Nano24 Overview
The cytokine storm is the most severe complication of a wide range of pulmonary and systemic diseases with an urgent unmet need, leading to more than 60M patients with 15M deaths per year. Utilising two breakthroughs, CD24 (the drug), and Exosomes (the carrier), Nano24 has developed the next generation of immunomodulators proving to solve the cytokine storm. EXO- CD24 is the first clinically tested, IP protected, exosomal based drug derived from genetically manipulated human embryonic cells. As a platform, EXO-CD24 has the potential to address many unmet indications, such as ARDS, SEPSIS, Cardiogenic Shock and many more. As a first step, Nano24 focuses on the ARDS market, which has no medical therapy, is responsible for 10-20% general admissions to ICU and causes 1.2 million deaths per year (similar to the world wide annual deaths from car accidents). After clinical trials phases Ib+IIa and IIb (dose finding study), the results showed extremely high success, with no deaths caused by the cytokine storm, duration of hospitalisation dramatically reduced and no any side effects. Nano24 (formerly OBCTCD24) was established in June 2020, based on 25 years of knowledge and experience accumulated in the lab of Dr. Shapira and Prof. Arber.
Cumulative Funding Raised Over Time ($)
Latest News
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $9.5M |
| Last funding | $1.4M |
| Stage | Seed |
| Rounds | 4 |
| Investors | 1 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | nano24med.com/ |
Locations
Weizmann St 6, Tel Aviv-Yafo, Israel
Photos & Videos
1 item(s)
Nano24 Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesHealthcareCore Technology
BiologicalsGenesMicroorganismsMoleculesCellsTags (13)
drug-developmentantibodiespharma-companiesimmunotherapytargetingbiopharmaceuticaltargeted-therapygeneticsimmunologypreventionnanotechnologybiotechnologydrug-discoveryGeographic Markets
GlobalNano24 Financials
Cumulative Funding Raised Over Time ($)
Private Equity Funding
Non-Equity Funding
Nano24 Lifecycle
Cumulative Funding Raised Over Time
All Events
Nano24 News
1 articleNano24 Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 2 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Nano24 Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516204989 |
| Phone | +972524266595 |
| Creator | Liviu Babitz |
| Creator email | liviu@nano24med.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-10-01T00:00:00.000Z |
| Created | 2023-07-04T00:00:00.000Z |
| Claimed | Yes |